CureVac’s COVID-19 vaccine failed in preliminary trial results


A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was due largely to the difficulties posed by new variants.

The company’s 40,000 person trial was conducted in 10 countries in Latin America and Europe, where “at least” 13 different variants were circulating. The 47 percent efficacy result, while not final, is the lowest reported to date from any COVID-19 vaccine manufacturer.

CureVac is backed by the Bill & Melinda Gates Foundation, which invested $52 million. Its vaccine relies on mRNA technology, similar to what is used in the successful Pfizer-BioNTech and Moderna vaccines.